tbuckley/cabot-search huggingface dataset:
High Concentration of Immunoglobulin Allows Long-Lasting Suppression of Allo-Immune Reaction By Directly Inhibiting T-Cell Activation
Authors: Hideaki Maeba, Rie Kuroda, Masaki Fukuda, Toshihiro Fujiki, Shintaro Mase, Raita Araki, Yasuhiro Ikawa, Shoichi Koizumi, Akihiro Yachie, Ryosei Nishimura
Journal: Blood (2014)
Rising Percentages of Blasts Are Associated with Continuously Increasing Frequencies of FLT3-ITD and NPM1 Mutations In AML and In Addition Depend on Combinations of These Markers: Analysis of 805 Cases with Normal Karyotype AML.
Authors: Torsten Haferlach, Ulrike Bacher, Tamara Alpermann, Claudia Haferlach, Wolfgang Kern, Susanne Schnittger
Journal: Blood (2010)
What draws the line between perception and cognition?
Authors: Martin Rolfs, Michael Dambacher
Journal: Behavioral and Brain Sciences (2016)

Abstract The investigation of top-down effects on perception requires a rigorous definition of what qualifies as perceptual to begin with. Whereas Firestone &amp; Scholl's (F&amp;S's) phenomenological demarcation of perception from cognition appeals to intuition, we argue that the dividing line is best attained at the functional level. We exemplify how this approach facilitates scrutinizing putative interactions between judging and perceiving.
Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study
Authors: Ramesh K. Ramanathan, Ronald L. Korn, Natarajan Raghunand, Jasgit C. Sachdev, Ronald G. Newbold, Gayle Jameson, Gerald J. Fetterly, Joshua Prey, Stephan G. Klinz, Jaeyeon Kim, Jason Cain, Bart S. Hendriks, Daryl C. Drummond, Eliel Bayever, Jonathan B. Fitzgerald
Journal: Clinical Cancer Research (2017)

Purpose: To determine whether deposition characteristics of ferumoxytol (FMX) iron nanoparticles in tumors, identified by quantitative MRI, may predict tumor lesion response to nanoliposomal irinotecan (nal-IRI).Experimental Design: Eligible patients with previously treated solid tumors had FMX-MRI scans before and following (1, 24, and 72 hours) FMX injection. After MRI acquisition, R2* signal was used to calculate FMX levels in plasma, reference tissue, and tumor lesions by comparison with a phantom-based standard curve. Patients then received nal-IRI (70 mg/m2 free base strength) biweekly until progression. Two percutaneous core biopsies were collected from selected tumor lesions 72 hours after FMX or nal-IRI.Results: Iron particle levels were quantified by FMX-MRI in plasma, reference tissues, and tumor lesions in 13 of 15 eligible patients. On the basis of a mechanistic pharmacokinetic model, tissue permeability to FMX correlated with early FMX-MRI signals at 1 and 24 hours, while FMX tissue binding contributed at 72 hours. Higher FMX levels (ranked relative to median value of multiple evaluable lesions from 9 patients) were significantly associated with reduction in lesion size by RECIST v1.1 at early time points (P < 0.001 at 1 hour and P < 0.003 at 24 hours FMX-MRI, one-way ANOVA). No association was observed with post-FMX levels at 72 hours. Irinotecan drug levels in lesions correlated with patient's time on treatment (Spearman ρ = 0.7824; P = 0.0016).Conclusions: Correlation between FMX levels in tumor lesions and nal-IRI activity suggests that lesion permeability to FMX and subsequent tumor uptake may be a useful noninvasive and predictive biomarker for nal-IRI response in patients with solid tumors. Clin Cancer Res; 23(14); 3638-48. ©2017 AACR.
Randomized phase II trial of maintenance sunitinib versus placebo following response to chemotherapy (CT) for patients (pts) with advanced urothelial carcinoma (UC).
Authors: Petros Grivas, David M. Nanus, Walter Michael Stadler, Stephanie Daignault, Robert Dreicer, Manish Kohli, Daniel Peter Petrylak, David J. Vaughn, Kathryn A. Bylow, Arie S. Belldegrun, Joseph L. Sottnik, Evan T. Keller, David C. Smith, Maha Hussain
Journal: Journal of Clinical Oncology (2012)

265 Background: UC response to CT is not durable. Angiogenesis may play a role in the progression of UC. We evaluated whether maintenance sunitinib delays progression after response to CT. Methods: Pts with ECOG PS 0-2, adequate organ function, stable disease, partial or complete response (SD, PR, CR) after 4-6 cycles of CT for advanced UC were randomized to oral sunitinib 50 mg/day, 28 days on, 14 days off (6-week cycle) or placebo. Disease was assessed every 12 wks. At progression, placebo pts were offered open label sunitinib. Primary endpoint: progression rate at 6 months (ms); secondary endpoints: safety, objective response rate, survival, VEGF/sVEGFR2 serum level changes. Using a randomized selection design 42 pts/arm has 90% probability of selecting sunitinib if true reduction in 6-ms progression rate is 15% (from 50% to 35%). Results: Study was closed early due to slow accrual. 54 pts with median age 69 years, median ECOG PS 1, 70% with bladder primary, 26 with SD, 23 with PR, 5 with CR to CT were randomized to sunitinib (26) or placebo (28). The median number of cycles was 2/arm (sunitinib 0-15, placebo 0-13). The 6-ms progression rate was 81% (95%CI 61-93%), median time-to-progression (TTP) 5 ms (0.3-22.2, 95%CI 2.4-6.3) for sunitinib and 75% (95%CI 55-89%), 2.7 ms (0.8-19.6, 95%CI 2.5-7.4) for placebo. Response rate in pts with SD at enrollment was 9% for sunitinib and 7% for placebo. Most common G3/4 AEs on sunitinib were diarrhea (15.4%/0%), fatigue (15.4%/3.8%), thrombocytopenia (15.4%/7.7%), hypertension (11.5%/0%). 16 placebo pts received sunitinib with best response 1 PR (6.25%), 6 SD (37.5%), 5 PD (31.25%); 4 not response evaluable. Median TTP was 3.4 ms (0.1-22, 95%CI 1.6-5.5). 11 pts had G3/4 AEs, 5 pts discontinued sunitinib due to AEs (4 related, 1 unrelated). Placebo pts had no change in VEGF/sVEGFR2 over time. Sunitinib pts had no change in VEGF but sVEGFR2 significantly decreased after 1 cycle (p&lt;0.0001) and at progression (p=0.0002). VEGF/sVEGFR2 did not correlate with TTP. Conclusions: Maintenance sunitinib was feasible but did not improve 6-ms progression rate; open label sunitinib had limited activity. sVEGFR-2 decreased on sunitinib.
Primed-G-CSF BMT for Children with Fanconi Anemia (FA) Using Mycophenolate Mofetil (MMF) and Cyclosporine-A for Gvhd Prophylaxis: Rapid Neutrophil Engraftment, Less Mucositis and Low Incidence of Chronic Gvhd
Authors: Fabiana Ostronoff, Mauricio Ostronoff, ANA Patricia Souto Maior, Rodolfo Calixto, Monique Martins, Mariana Coutinho, Alexandre Sucupira, Luis Fabio Botelho, Rodrigo Florencio
Journal: Blood (2010)
Perception, as you make it
Authors: David W. Vinson, Drew H. Abney, Dima Amso, Anthony Chemero, James E. Cutting, Rick Dale, Jonathan B. Freeman, Laurie B. Feldman, Karl J. Friston, Shaun Gallagher, J. Scott Jordan, Liad Mudrik, Sasha Ondobaka, Daniel C. Richardson, Ladan Shams, Maggie Shiffrar, Michael J. Spivey
Journal: Behavioral and Brain Sciences (2016)

The main question that Firestone & Scholl (F&S) pose is whether "what and how we see is functionally independent from what and how we think, know, desire, act, and so forth" (sect. 2, para. 1). We synthesize a collection of concerns from an interdisciplinary set of coauthors regarding F&S's assumptions and appeals to intuition, resulting in their treatment of visual perception as context-free.
Photobiomodulation for the prevention of radiodermatitis: Preliminary results of a randomized controlled clinical trial in breast cancer patients
Authors: J. Robijns, S. Censabella, S. Claes, L. Bussé, N. Hellings, I. Lambrichts, A. Timmermans, A. Maes, P. Bulens, V. Somers, J. Mebis
Journal: Annals of Oncology (2016)
ANGI-13HISTOPATHOLOGICAL INVESTIGATION OF GLIOBLASTOMAS RESECTED UNDER CONTROL OF NEOADJUVANT BEVACIZUMAB
Authors: Ryota Tamura, Keisuke Miyake, Toshihide Tanaka, Yusuke Tabei, Kentaro Ohara, Sampetrean Oltea, Takashi Tamiya, Kazunari Yoshida, Hikaru Sasaki
Journal: Neuro-Oncology (2015)

There has been no clinical observation about histopathological changes in human gliomas under control of the anti-angiogenic treatment, and the tissue-based observation is likely crucial to understand mechanism of action of these treatment. We collected 4 glioblastomas resected under control of neoadjuvant bevacizumab (Bev). Histopathological investigation was performed by hematoxilyn- eosin staining and immunohistochemistry for CD34, VEGF, VEGFR1/2, HIF-1α, and Nestin as compared to 6 control glioblastomas to assess changes in histological features, microvessel density, expression of VEGF and its receptors, tumor hypoxic condition, and cancer stem cells. Tumor resection under control of Bev was uneventful in all of the 4 cases. Intraoperatively, the tumors were clearly less vasculized than usual. Histopathologically, vascular morphology was quite different from usual glioblastomas with universal disappearance of microvascular proliferation. Microvessel density was significantly decreased in the 4 tumors as compared to control tumors. The expression of VEGF and its receptors was decreased in 2 cases of partial response, suggesting possible correlation with radiologic response. The expression of HIF-1α was similar or somewhat decreased in the 4 tumors. The expression of Nestin was significantly decreased in the 4 tumors as compared to control tumors, but there still remained numerous Nestin-positive cells especially around vessels. We provide the first clinicopathological evidence that the anti-angiogenic therapy induces vascular normalization and decrease of microvessel density in glioblastomas. These in situ observation will help to elucidate the mechanism of resistance to Bev and to optimize therapy.
Retreatment with trastuzumab (T)-based therapy in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC) resistant to lapatinib (L)-based therapy.
Authors: S. Gori, F. Montemurro, S. Spazzapan, G. Metro, J. Foglietta, G. Bisagni, A. Ferzi, R. R. Silva, T. Gamucci, M. Clavarezza, L. Stocchi, A. Fabi, F. Cognetti, E. Torrisi, D. Crivellari
Journal: Journal of Clinical Oncology (2011)

568 Background: Preclinical data suggest that treatment with lapatinib may reinduce sensitivity to trastuzumab in HER2+ breast cancer cells (Scaltriti, Oncogene 2009;28:803). We evaluated the activity of retreatment with T-based therapy after L in HER2+ MBC pts. Methods: 69 HER2+ MBC pts retreated with T after L progression were identified using pharmacy records from 9 Italian Institutions (Jan 2007-Nov 2010). Response to T retreatment, post-T progression-free survival (PFS) and overall survival (OS) were evaluated. Results: Pts median age was 57 y (26-79); ECOG PS was 0-1 in 77% (53/69), 2 in 7% (5/69) and not registered for 16% (11/69) of the pts; 51 pts (74%) had visceral metastases and 16 (23%) brain metastases with or without visceral involvement. All pts were pretreated with both T- and L-based therapy for MBC, and 11 had also received adjuvant T. The median number of chemotherapeutic lines for MBC before L was 2 (range 0-8) including a median of 2 (0-6) T-based regimens. The median duration of L was 5.7 months (range 0.7-19.5). Retreatment with T was associated with a clinical benefit rate of 42%, including 1 CR (1.4%), 18 PRs (26%) and 10 SDs lasting ≥ 6 months (14%). The median duration of response was 8.1 months (95% C.I. 5.5-10.7). At a median follow up of 13 months, median PFS was 4.9 months (95% CI 4.2-5.6) and median OS 19.5 months (95%CI 14.0-25.0). Median OS was longer for pts experiencing clinical benefit (not reached vs 13.4 months for pts without CB, p= 0.002). CNS involvement was associated with lower median OS (17.3 months vs 23.3 months for patients without CNS involvement; p= 0.021). Conclusions: Retreatment with T-based therapy showed clinical benefit in 42% of pts progressing during L-based therapy. The prolonged OS observed in pts achieving a clinical benefit suggests that the sensitivity to trastuzumab re-induced by lapatinib in HER2+ breast cancer cells might have clinical implications that merit future prospective studies.
Anticoagulant Effects of the Low-Molecular-Weight Heparin Certoparin in Combination with Phenprocoumon in Patients with Recent Atrial Fibrillation Undergoing Cardioversion
Authors: Job Harenberg, Jolanta Wierdack, Christel Weiss, Christina Giese, Claudia Abletshauser, Ulrich Tebbe
Journal: Blood (2008)
Imatinib Combined with Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Versus Imatinib Alone for Young Patients with Chronic Myeloid Leukemia in Chronic Phase
Authors: Yanmin Zhao, Yi Luo, Yamin Tan, Jimin Shi, Zhen Cai, Maofang Lin, He Huang
Journal: Blood (2014)
Outcomes Associated With Paroxysmal Supraventricular Tachycardia During Pregnancy
Authors: Shang-Hung Chang, Chang-Fu Kuo, I-Jun Chou, Lai-Chu See, Kuang-Hui Yu, Shue-Fen Luo, Meng-Jiun Chiou, Weiya Zhang, Michael Doherty, Ming-Shien Wen, Wei-Jan Chen, Yung-Hsin Yeh
Journal: Circulation (2017)
Whole Liver Iron Overload Measurement by Magnetic Iron Detector (MID). A Non Cryogenic Bio-Susceptometer.
Authors: Mauro Marinelli, Piergiorgio Beruto, Barbara Gianesin, Antonella Lavagetto, Martina Lamagna, Eraldo Oliveri, Maria Luigia Saccone, Giuliano Sobrero, Laura Terenzani, Gian Luca
Journal: Blood (2006)
Long Term Toxicity and Follow-up of Waldenstrom´s Macroglobulinemia Patients after Salvage Treatment with Fludarabine Cyclophosphamide Rituximab or Bendamustine and Rituximab
Authors: Alessandra Tedeschi, Paola Picardi, Maria Cecilia Goldaniga, Gloria Margiotta Casaluci, Giulia Benevolo, Simone Ferrero, Marzia Varettoni, Claudia Baratè, Guido Gini, Carlo Visco, Marina Motta, Valeria Belsito Petrizzi, Francesco Zaja, Erica Ravelli, Massimo Gentile, Anna Maria Frustaci, Lorella Orsucci, Enrica Morra, Gianluca Gaidano, Roberto Cairoli
Journal: Blood (2015)
Insomnia is linked to higher risk of developing asthma
Authors: Jacqui Wise
Journal: BMJ (2017)

People with chronic insomnia are three times more likely to develop asthma than those without sleep problems, a study in the European Respiratory Journal suggests.1

Insomnia is known to be highly prevalent among asthmatic patients, as studies indicate a prevalence of 44-70%, compared with 7-37% in the general population. However, until now no prospective studies had investigated whether insomnia patients have a higher risk of developing asthma at a later stage.

The researchers used data from the Nord-Trondelag Health Study (HUNT), an ongoing health survey of the adult population …
Agrin is a major heparan sulfate proteoglycan in the human glomerular basement membrane
Authors: A.J. Groffen, M.A. Ruegg, H. Dijkman, T.J. van de Velden, C.A. Buskens, J. van den Born, K.J. Assmann, L.A.H. Monnens, J.H. Veerkamp, L.P. van den Heuvel
Journal: Journal of the American Society of Nephrology (1997)
Isolation of the Stromal/Vascular Fraction of Murine Bone Marrow Dramatically Enhances MSC Yield, Allows Isolation of Marrow Endothelial Cells and Reveals Multiple Subpopulations of Stromal Cells.
Authors: Colby G. Suire, Nathalie Brouard, Brian Blaugrund, Paul J. Simmons
Journal: Blood (2010)
Favourable Outcome in Infants with Acute Myeloid Leukemia Treated with the AIEOP AML 2002/01 Protocol
Authors: Riccardo Masetti, Martina Pigazzi, Andrea Pession, Carmelo Rizzari, Nicola Santoro, Luca lo Nigro, Matteo Luciani, Giuseppe Menna, Roberto Rondelli, Giuseppe Basso, Franco Locatelli
Journal: Blood (2012)
Update on Phase I Clinical Trial of IPI-504, a Novel, Water-Soluble Hsp90 Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM).
Authors: David Siegel, Sundar Jagannath, Amitabha Mazumder, David Vesole, Ivan Borrello, Jens Sydor, Jim Wright, Jon Patterson, Emmanuel Normant, Julian Adams, Kenneth Anderson, David Grayzel, Paul Richardson
Journal: Blood (2006)
Interphase FISH-Defined Amplification of Chromosome 1q21 (AMP1q21) Identify High-Risk Subsets among Patients with Multiple Myeloma (MM) Lacking Metaphase Cytogenetic Abnormalities (CA).
Authors: John Shaughnessy, Ichiro Hanamura, Bart Burington, Jeffrey Sawyer, John Crowley, Bart Barlogie
Journal: Blood (2005)
Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study
Authors: Kathelijn Fischer, Roshni Kulkarni, Beatrice Nolan, Johnny Mahlangu, Savita Rangarajan, Giulia Gambino, Lei Diao, Alejandra Ramirez-Santiago, Glenn F Pierce, Geoffrey Allen
Journal: The Lancet Haematology (2017)
Body Composition as a Predictor of Toxicity in Patients Receiving Anthracycline and Taxane–Based Chemotherapy for Early-Stage Breast Cancer
Authors: Shlomit Strulov Shachar, Allison M. Deal, Marc Weinberg, Grant R. Williams, Kirsten A. Nyrop, Karteek Popuri, Seul Ki Choi, Hyman B. Muss
Journal: Clinical Cancer Research (2017)

Abstract Purpose: Poor body composition metrics (BCM) are associated with inferior cancer outcomes; however, in early breast cancer (EBC), there is a paucity of evidence regarding the impact of BCM on toxicities. This study investigates associations between BCM and treatment-related toxicity in patients with EBC receiving anthracyclines and taxane–based chemotherapy. Experimental Design: Pretreatment computerized tomographic (CT) images were evaluated for skeletal muscle area (SMA), skeletal muscle density (SMD), and fat tissue at the third lumbar vertebrae. Skeletal muscle index (SMI = SMA/height2) and skeletal muscle gauge (SMG = SMI × SMD) were also calculated. Relative risks (RR) are reported for associations between body composition measures and toxicity outcomes, after adjustment for age and body surface area (BSA). Results: BCM were calculated for 151 patients with EBC (median age, 49 years; range, 23–75 years). Fifty patients (33%) developed grade 3/4 toxicity, which was significantly higher in those with low SMI (RR, 1.29; P = 0.002), low SMG (RR, 1.09; P = 0.01), and low lean body mass (RR, 1.48; P = 0.002). Receiver operating characteristic analysis showed the SMG measure to be the best predictor of grade 3/4 toxicity. Dividing SMG into tertiles showed toxicity rates of 46% and 22% for lowest versus highest tertile, respectively (P = 0.005). After adjusting for age and BSA, low SMG (&amp;lt;1,475 units) was significantly associated with hematologic (RR, 2.12; P = 0.02), gastrointestinal grade 3/4 toxicities (RR, 6.49; P = 0.02), and hospitalizations (RR, 1.91; P = 0.05). Conclusions: Poor BCMs are significantly associated with increased treatment-related toxicities. Further studies are needed to investigate how these metrics can be used to more precisely dose chemotherapy to reduce treatment-related toxicity while maintaining efficacy. Clin Cancer Res; 23(14); 3537–43. ©2017 AACR.
Abstract A36: Function of GPR56 in metastasis dormancy of melanoma
Authors: Nancy Corson, Michelle Warren, Lei Xu
Journal: Cancer Research (2016)

Abstract Dormancy imposes significant challenges for cancer diagnosis and prognosis. We use pairs of metastatic melanoma cell lines that have different abilities to form metastases to investigate the molecular mechanisms of metastatic dormancy. We found that a novel receptor, GPR56, was down-regulated in highly metastatic melanoma cells compared with the poorly metastatic parental line. Re-expression of GPR56 in five different melanoma cell lines resulted in inhibition of metastasis formation in mouse lung. RNAseq analyses revealed that GPR56 might regulate the expression of genes involved in cellular homeostasis. Furthermore, our preliminary data show that GPR56 internalizes and degrades its ligand, TG2 from cell surface. TG2 is an ECM protein and functions to stabilize ECM and facilitate its signaling. The loss of TG2 resulting from GPR56 expression would disrupt ECM deposition and signaling in melanomas, ultimately leading to disturbance of cellular homeostasis of melanoma cells and their growth arrest. Taken together, we propose a model in which the novel receptor GPR56 sequesters metastatic melanomas at dormant states by down-regulating TG2 from cell surface and modulating cellular homeostasis. Citation Format: Nancy Corson, Michelle Warren, Lei Xu. Function of GPR56 in metastasis dormancy of melanoma. [abstract]. In: Proceedings of the AACR Special Conference on Tumor Metastasis; 2015 Nov 30-Dec 3; Austin, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(7 Suppl):Abstract nr A36.
Surgeon suspended for 12 months after decision to strike him off was quashed
Authors: Clare Dyer
Journal: BMJ (2017)

The BMJA consultant in oral surgery has been suspended by both doctors’ and dentists’ UK regulators after hearings into the circumstances surrounding the death of a patient whose teeth he removed.

Jan Carsten Radeke, who qualified in both medicine and dentistry in Frankfurt, Germany, worked at King’s College Hospital in London from 2002, becoming a consultant in 2008. He was registered with both the General Dental Council (GDC) and the General Medical Council (GMC).

King’s College Hospital NHS Foundation Trust referred him to the GDC in 2013 over allegations involving three patients. He was struck off in February 2015 after a fitness to practise hearing found misconduct in three operations and dishonesty in …
Outcome of Children Who Experience Disease Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies,
Authors: Rajinder PS Bajwa, Sandeep Soni, Tal Schechter, Adam Gassas, John J Doyle, India Sisler, Kamar Godder, David Tatman, Stephen Rumelhart, Jennifer Domm, Haydar Frangoul
Journal: Blood (2011)
Prophylactic administration of epinephrine in oxaliplatin-related hypersensitivity reaction.
Authors: S. Iwasa, T. Hamaguchi, K. Tada, T. Yanai, H. Hashimoto, T. E. Nakajima, K. Kato, Y. Yamada, Y. Shimada
Journal: Journal of Clinical Oncology (2011)

610 Background: Alongside disease progression or neurotoxicity, oxaliplatin-related hypersensitivity reaction is a common reason for treatment discontinuation and remains a critical issue. It is unclear whether prophylactic administration of epinephrine to patients with this severe hypersensitivity reaction is effective and safe. Methods: We retrospectively reviewed 839 consecutive colorectal cancer patients treated with oxaliplatin-containing regimens at our hospital between April 2005 and March 2010. The medical records of those patients who had received prophylactic epinephrine (1:1000 solution) were examined. Hypersensitivity reaction was graded according to CTCAE version 3.0. Results: Twelve patients (8 male and 4 female; median age, 66 years) had received prophylactic epinephrine. The hypersensitivity reaction, even though the patients were receiving prophylactic corticosteroid and antihistamine drugs, was grade 0/1/2/3 = 0/0/10/2. The median number of epinephrine doses administered was 6 (range, 1 to 21). The worst grade of hypersensitivity for rechallenge with oxaliplatin under prophylactic administration of epinephrine was grade 0/1/2/3 = 4/3/4/1. Reasons for treatment discontinuation were disease progression in 10 patients and neurotoxicity in one patient. The remaining one patient developed grade 3 hypersensitivity reaction during 4 cycles of treatment under prophylactic administration of epinephrine, but the reaction subsided after additional administration of epinephrine and corticosteroid. Common adverse events with administration of epinephrine were hypertension (4 patients), palpitation (3 patients) and headache, dizziness, fatigue, and bladder pain (1 patient each). Conclusions: Prophylactic administration of epinephrine may be effective and tolerated in patients with moderate to severe oxaliplatin-related hypersensitivity reaction. No significant financial relationships to disclose.